<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Study Finds That CTC Was Used Correctly In Medicare Patients

ASCO Draft Recommendations Define Meaningful Trial Outcomes

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

Alcohol Consumption Does Not Impact Survival of Breast Cancer

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

European Treatment Regimen Less Toxic Than American Method

Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant

NCI CTEP Approved Trials For the Month of April

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

Cuts Claimed to Displace “Millions” of Patients Yet None Seem to Complain. Why Not?